

Table S3. Specific reasons for exclusion.

Full-text articles excluded not matching inclusion criteria (n = 404)	
ANK	(n = 273) Different disease or study drug (n = 97) Non-RCT (n = 7) Others (n = 20) Post-hoc analysis (n = 1) Retrospective analysis (n = 3) Review (n = 5) Study size less than 3 patients (n = 99) Study without primary endpoint of interest (n = 41)
BER	(n = 2) Non RCT (n = 2)
CAN	(n = 55) Different disease or study drug (n = 21) Non-RCT (n = 4) Other (n = 3) Retrospective analysis (n = 3) Review (n = 3) Study included two diseases of interest (n = 3) Study size less than 3 patients (n = 11) Study without primary endpoint of interest (n = 7)
GEV	(n = 4) Different disease or study drug (n = 2) Non-RCT (n = 1) Study size less than 3 patients (n = 1)
RIL	(n = 70) Different disease or study drug (n = 9) Non-RCT (n = 3) Others (n = 3) Review (n = 48) Study size less than 3 patients (n = 1) Study without primary endpoint of interest (n = 6)

Abbreviations:

ANK, anakinra; BER, bermekimab; CAN, canakinumab; GEV, gevokizumab; RCT, randomized controlled trial; RIL, rilonacept,